The importance of appropriate antimicrobial dosing: Pharmacokinetic and pharmacodynamic considerations

被引:14
|
作者
Preston, SL [1 ]
机构
[1] Albany Med Coll, Clin Pharmacol Studies Unit, Albany, NY 12208 USA
关键词
D O I
10.1345/aph.1E218
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The increasing antimicrobial resistance of common respiratory pathogens has led to a reevaluation of the selection of antimicrobial dosing regimens in terms of their pharmacokinetic (PK) and pharmacodynamic (PD) properties. Pharmacokinetics, when considered as part of a specific dosing regimen, can help determine the time course of drug concentrations in the serum, tissues, body fluids, and at the site of infection. Pharmacodynamics provides surrogate markers for clinical and bacteriologic efficacy based on the relationships between the serum and tissue concentrations of selected antimicrobial agents relative to the mean inhibitory concentrations of causative bacteria over time. Ultimately, the interrelationships between PK and PD parameters measured for standard dosing regimens determine the time course of the drug's concentration at the site of infection and the impact of the agent's bacteriologic and clinical efficacy. In this review, the distinctive patterns of antimicrobial activity based on PK/PD parameters are discussed. Various antibiotics and bacterial pathogens are used as models to demonstrate the utility of PK/PD parameters in predicting the in vivo efficacy of antimicrobial therapy. The use of computer modeling with Monte Carlo population simulations can further enhance the predictability of antimicrobial efficacy when using PK/PD parameters. This article also provides a reevaluation of bacterial susceptibility breakpoints defined by the National Committee for Clinical Laboratory Standards contrasted with the use of PK/PD parameters.
引用
收藏
页码:S14 / S18
页数:5
相关论文
共 50 条
  • [21] Geriatric Psychopharmacology: Pharmacokinetic and Pharmacodynamic Considerations
    Carlo, Andrew D.
    Alpert, Jonathan E.
    PSYCHIATRIC ANNALS, 2015, 45 (07) : 336 - 341
  • [22] Pharmacodynamic and pharmacokinetic considerations in geriatric psychopharmacology
    Catterson, ML
    Preskorn, SH
    Martin, RL
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1997, 20 (01) : 205 - &
  • [23] Donepezil Dosing Strategies: Pharmacokinetic Considerations
    Gomolin, Irving H.
    Smith, Candace
    Jeitner, Thomas M.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2011, 12 (08) : 606 - 608
  • [24] PHARMACOKINETIC CONSIDERATIONS IN PEDIATRIC DIGOXIN DOSING
    KUMER, KP
    NWANGWU, PU
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1981, 30 (02): : 265 - 270
  • [25] Antimicrobial Dosing Individualization Based on Pharmacokinetic/Pharmacodynamic Evaluation, Considering Factors of " Patient " , " Site of infection" " and " Microorganism "
    Onita, Tetsushu
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2024, 144 (10): : 937 - 943
  • [26] PERMANENT PDA CLOSURE WITH PHARMACOKINETIC PHARMACODYNAMIC DOSING OF INDOMETHACIN
    GAL, P
    SCHALL, S
    RANSOM, JL
    WEAVER, RL
    WYBLE, LE
    CARLOS, RQ
    BROWN, Y
    PEDIATRIC RESEARCH, 1991, 29 (04) : A243 - A243
  • [27] RATIONAL WARFARIN DOSING - A PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS
    HOLFORD, NHG
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (02) : 199 - 199
  • [28] Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis
    Sherwin, Catherine M. T.
    Svahn, Sofia
    Van Der Linden, Antje
    Broadbent, Roland S.
    Medlicott, Natalie J.
    Reith, David M.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (07) : 705 - 713
  • [29] Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing
    Onufrak, Nikolas J.
    Forrest, Alan
    Gonzalez, Daniel
    CLINICAL THERAPEUTICS, 2016, 38 (09) : 1930 - 1947
  • [30] Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis
    Catherine M. T. Sherwin
    Sofia Svahn
    Antje Van Der Linden
    Roland S. Broadbent
    Natalie J. Medlicott
    David M. Reith
    European Journal of Clinical Pharmacology, 2009, 65